

User Manual – Pathways – Patient

In order to access Pathways as a patient, the user must navigate to <u>http://gstt-</u> <u>pathways.cloudapp.net/</u> in a browser, which will then redirect him/her to the Pathways homepage. The patient will have to enter their credentials in the login form at the bottomleft part of the screen, as you may see in the following picture.





After entering their credentials, the patient will be redirected to the categories pages, which contains all the information assigned to them contained in several main categories, allowing for easier navigation by the patient.

PATHWAYS	NHS Guy's and St Thomas' Logout
Signed in successfully.	
	Welcome to your hub, John Smith Access your treatment information via the buttons below.
Chemotherapy	Radiotherapy
Pathways is a tool for you	Patient Pathways - by the Guy's and St. Thomas' Hospital Trust. to access your past, present and future treatment information, it is not a substitute for your doctor. In an emergency always call 999. Click to view the End User Liense Agreement @ 2015 Guy's and St. Thomas' NHS Foundation Trust.



By clicking any of these categories, the patient is redirected to a page where all the information related to that specific category is displayed in an easy to read manner. This page features a timeline of data updates within the category, and a patient may navigate through this timeline by clicking the dates available at the bottom of the page. This will show the patient the set of information assigned on the date they selected.

PATHWAYS	NHS	Guy's and St Thomas'	Logout
	Home / Category: Chemotherapy		
	Palliative Specific		
	⊕ Targeted therapy for stomach cancer		
	Occasionally, a targeted therapy drug called trastuzumab (Herceptin®) is given with chemotherapy for advanced stomach cancer.		
	Targeted therapy drugs interfere with the way cancer cells grow. Trastuzumab only works for people with a stomach cancer that has high levels of a protein called HER2. About 1 in 5 people with stomach cancer (20%) have this. Tests can be done on tissue taken at a biopsy or during surgery to find out if the cancer cells have high levels of HER2.		
	Trastuzumab attaches to the HER2 proteins on the surface of the cancer cells. This stops the cancer cells from dividing and growing.		
	Trastuzumab is given as a drip (infusion) every three weeks. If it works well, your doctor may decide to carry on giving it after your chemotherapy has stopped. The side		
	effects of trastuzumab are usually mild.		
	Doctors are testing other targeted therapy drugs in clinical trials.		
Curative			
	⊕ ECX chemotherapy		
	⊕ ECF chemotherapy		
	Chemotherapy for stomach cancer		
	Approximately 12/06/2016		